Sentences with phrase «erlotinib for»

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

Not exact matches

The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

For example, epidermal growth factor (EGFR) mutations may result in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.

They also analysed the patients» cancers for mutations in two other molecules, one called EGFR which is the target of existing drugs gefitinib and erlotinib, and another called KRAS.

Researchers and physicians have shown success treating EGFR lung cancer, for example with EGFR inhibitors gefitinib and erlotinib.

Kinases are also druggable targets, as seen by the success of kinase - inhibitors in earning FDA approval (including, for example, crizotinib against ALK - fusion and erlotinib against EGFR).

Niclosamide may work as therapeutic for familial adenomatosis polyposis (FAP) by disrupting the axin - GSK3 interaction and for colon cancer in synergizing with erlotinib [52,53].

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).

[21] In the recently presented FLAURA study, in which osimertinib was used in untreated patients with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients with brain metastases.

[29] The Radiation Therapy Oncology Group study 0320 evaluated WBRT + stereotactic radiosurgery (SRS) + erlotinib and found significant grade 3 — 5 toxicity rates of 49 %, compared with a rate of 11 % for WBRT alone; the toxicities observed included cytopenias, rash, fatigue, and dehydration, among others.

The drug erlotinib is prescribed to between 10 - 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

The HR for progression for docetaxel vs. erlotinib was 0.70 (P =.019).

For both populations, though, disease prognosis remains poor: the median progression - free survival for docetaxel - treated patients was 3.4 months, compared with 2.4 months for erlotinFor both populations, though, disease prognosis remains poor: the median progression - free survival for docetaxel - treated patients was 3.4 months, compared with 2.4 months for erlotinfor docetaxel - treated patients was 3.4 months, compared with 2.4 months for erlotinfor erlotinib.